Terms: = Bone cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Prognosis
1270 results:
1. Upregulation of circ_0076684 in osteosarcoma facilitates malignant processes by mediating miRNAs/CUX1.
Cai P; Fu X; Li X; Zhao W
J Orthop Surg Res; 2024 Apr; 19(1):260. PubMed ID: 38659042
[TBL] [Abstract] [Full Text] [Related]
2. ZNF692 promotes osteosarcoma cell proliferation, migration, and invasion through TNK2-mediated activation of the MEK/ERK pathway.
Zheng D; Wei Z; Zhang C; Liu W; Gong C; Wu F; Guo W
Biol Direct; 2024 Apr; 19(1):28. PubMed ID: 38650011
[TBL] [Abstract] [Full Text] [Related]
3. VDR is a potential prognostic biomarker and positively correlated with immune infiltration: a comprehensive pan-cancer analysis with experimental verification.
Xia X; Xu F; Dai D; Xiong A; Sun R; Ling Y; Qiu L; Wang R; Ding Y; Lin M; Li H; Xie Z
Biosci Rep; 2024 May; 44(5):. PubMed ID: 38639057
[TBL] [Abstract] [Full Text] [Related]
4. Transient Receptor Potential Ankyrin 1 Ion Channel Is Expressed in Osteosarcoma and Its Activation Reduces Viability.
Hudhud L; Rozmer K; Kecskés A; Pohóczky K; Bencze N; Buzás K; Szőke É; Helyes Z
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612571
[TBL] [Abstract] [Full Text] [Related]
5. Vitexicarpin Induces Apoptosis and Inhibits Metastatic Properties via the AKT-PRAS40 Pathway in Human Osteosarcoma.
Yun HM; Kwon HS; Lee JY; Park KR
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612399
[TBL] [Abstract] [Full Text] [Related]
6. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Gaumond SI; Abdin R; Costoya J; Schally AV; Jimenez JJ
Oncotarget; 2024 Apr; 15():248-254. PubMed ID: 38588464
[TBL] [Abstract] [Full Text] [Related]
7. Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues.
Sun X; Chang J; Zhou C; Zhao P; Guo S; Tong J; Wang Y; Yang Y
J Vis Exp; 2024 Mar; (205):. PubMed ID: 38587398
[TBL] [Abstract] [Full Text] [Related]
8. Immune microenvironment of human papillomavirus-positive head and neck squamous cell carcinoma.
Zhu D; He X; Li Y; Li G; Chen M
Sci Prog; 2024; 107(1):368504241237888. PubMed ID: 38545800
[TBL] [Abstract] [Full Text] [Related]
9. Transcriptome free energy can serve as a dynamic patient-specific biomarker in acute myeloid leukemia.
Uechi L; Vasudevan S; Vilenski D; Branciamore S; Frankhouser D; O'Meally D; Meshinchi S; Marcucci G; Kuo YH; Rockne R; Kravchenko-Balasha N
NPJ Syst Biol Appl; 2024 Mar; 10(1):32. PubMed ID: 38527998
[TBL] [Abstract] [Full Text] [Related]
10. Artificial Intelligence in bone Metastasis Imaging: Recent Progresses from Diagnosis to Treatment - A Narrative Review.
Caloro E; Gnocchi G; Quarrella C; Ce M; Carrafiello G; Cellina M
Crit Rev Oncog; 2024; 29(2):77-90. PubMed ID: 38505883
[TBL] [Abstract] [Full Text] [Related]
11. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA; Long MD; Kosaka Y; Long N; Mulkey JS; Coy JL; Agarwal A; Lind EF
Front Immunol; 2024; 15():1297338. PubMed ID: 38495876
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
Bauer M; Jäkel N; Wilfer A; Haak A; Eszlinger M; Kelemen K; Haemmerle M; Al-Ali HK; Seliger B; Wickenhauser C
Oncoimmunology; 2024; 13(1):2323212. PubMed ID: 38481730
[TBL] [Abstract] [Full Text] [Related]
13. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
Zeissig MN; Hewett DR; Mrozik KM; Panagopoulos V; Wallington-Gates CT; Spencer A; Dold SM; Engelhardt M; Vandyke K; Zannettino ACW
Leuk Res; 2024 Apr; 139():107469. PubMed ID: 38479337
[TBL] [Abstract] [Full Text] [Related]
14. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
[TBL] [Abstract] [Full Text] [Related]
15. The Effects of Fucoidan Derived from
Gupta D; Martinez DC; Puertas-Mejía MA; Hearnden VL; Reilly GC
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396762
[TBL] [Abstract] [Full Text] [Related]
16. Integrated transcriptomic analysis systematically reveals the heterogeneity and molecular characterization of cancer-associated fibroblasts in osteosarcoma.
Liu Y; Han X; Han Y; Bi J; Wu Y; Xiang D; Zhang Y; Bi W; Xu M; Li J
Gene; 2024 May; 907():148286. PubMed ID: 38367852
[TBL] [Abstract] [Full Text] [Related]
17. Synthesis, Quality Control, and Bench-to-Bed Translation of a New [
Chakraborty S; Chatterjee S; Chakravarty R; Sarma HD; Nanabala R; Goswami D; Joy A; Pillai MRA
Cancer Biother Radiopharm; 2024 Feb; 39(1):92-101. PubMed ID: 38335449
[No Abstract] [Full Text] [Related]
18. Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.
Yu W; Zhou M; Niu H; Li J; Li Q; Xu X; Liang F; Rui C
BMC Cancer; 2024 Jan; 24(1):140. PubMed ID: 38287266
[TBL] [Abstract] [Full Text] [Related]
19. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract] [Full Text] [Related]
20. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers.
Lan H; Wu B; Jin K; Chen Y
Front Endocrinol (Lausanne); 2023; 14():1260491. PubMed ID: 38260135
[TBL] [Abstract] [Full Text] [Related]
[Next]
